Opexa Therapeutics, Inc. (OPXA) Starts Presentation at 2015 Marcum MicroCap Conference

Opexa Therapeutics is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The company’s leading therapy candidate, Tcelna®, is in a phase 2b clinical development program for the treatment of secondary progressive MS. For more information, visit the company’s website at www.opexatherapeutics.com.